vildagliptin / Generic mfg. - LARVOL DELTA

Vildagliptin-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE): A Rare Case Report (EADV 2026) - No abstract available

Case report • Clinical

Vildagliptin-induced bullous Pemphigoid (EADV 2026) - No abstract available

Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology

In Silico Identification of Novel Leads as Potential DPP-IV Inhibitors as Antidiabetic Agents Using Virtual Screening. (PubMed, ACS Omega) - "MM/GBSA analysis confirmed stronger binding energies for EOS34295 (-56.58 kcal/mol), EOS62725 (-37.90 kcal/mol), and EOS2567 (-31.27 kcal/mol) relative to vildagliptin (-23.88 kcal/mol). This study identifies EOS34295, EOS2567, and EOS62725 emerged as promising DPP-IV inhibitory hits with superior binding stability, supporting their potential as antidiabetic leads for future experimental validation."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (clinicaltrials.gov) - P4 | N=92 | Completed | Sponsor: Fundacin para la Investigacin del Hospital Clnico de Valencia | N=504 ➔ 92 | Active, not recruiting ➔ Completed

Biomarker • Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Vildagliptin-Induced Leukocytoclastic Vasculitis: A Case Report and Review of Published Cases. (PubMed, Am J Ther) - No abstract available

Journal • Vasculitis

Comparative validation of DPP4, CD36 and EGFR inhibition in mitigating lipotoxic beta cell dysfunction: targeting inflammation vs lipid overload (EASD 2026) - "Overall, the findings suggest that reducing intracellular lipid accumulation is central to restoring beta cell function in hyperlipidemia. Erlotinib and Vildagliptin are more effective in reducing TLR4-NFkB-mediated inflammation, with Erlotinib exhibiting better efficacy in improving insulin secretion. However, SalB offers an advantage in mitigating lipid accumulation, indicating that optimal therapeutic choice may depend on targeting inflammation vs lipid overload in the pancreatic beta cells."

Diabetes • Metabolic Disorders • Obesity • AHSG • CD36 • IL1B • SCARB1 • TLR4

Probable Vildagliptin-Associated Acute Pancreatitis in a Patient With Well-Controlled Type 2 Diabetes Mellitus: A Case Report. (PubMed, Cureus) - "We report the case of a 46-year-old man with well-controlled type 2 diabetes mellitus who presented with severe epigastric pain radiating to the back after six months of therapy with vildagliptin and metformin. The temporal association, exclusion of alternative causes, and improvement following drug withdrawal (positive dechallenge), together with a Naranjo Adverse Drug Reaction Probability Scale score of 7, support a probable drug-related association, with vildagliptin considered the most likely causative agent. Clinicians should remain aware of this rare but potential adverse effect when evaluating patients receiving DPP-4 inhibitors who present with acute pancreatitis after exclusion of more common causes."

Journal • Diabetes • Dyslipidemia • Endocrine Disorders • Gastroenterology • Hypertriglyceridemia • Metabolic Disorders • Pain • Pancreatitis • Type 2 Diabetes Mellitus

Comparison of the permeability of DPP-4 inhibitors-sitagliptin, vildagliptin, linagliptin, and alogliptin-in placental barrier cell models and exploration of their transport mechanisms by LC-MS/MS. (PubMed, BMC Pregnancy Childbirth) - "Vildagliptin had the lowest accumulation and permeability in placental cells among the four DPP-4 inhibitors. There might be carrier-mediated transmembrane transport of linagliptin, alogliptin, sitagliptin and vildagliptin, but ENTs, CNTs and OAT4 were not involved in. This study provides a basis for future research on their safety during pregnancy."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's). (PubMed, Chem Biodivers) - "Molecular docking studies revealed four promising lead candidates, that is, YS-3, YS-5, YS-14, and YS-15 (>-138.26 kcal/mol in DPP IV while >-150.29 kcal/mol in PTP1B), with higher binding affinities as compared to clinical standard inhibitors, Vildagliptin (-103.46 kcal/mol; DPP IV) and Ertiprotafib (-141.91 kcal/mol; PTP 1B)...DFT-based electronic profiling and ADMET predictions confirmed the biological viability and drug-like properties. These findings provide a robust structural blueprint for DDPI's with improved affinity, along with a better understanding of the inhibitory mechanisms."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • DPP4 • PTPN1

Phosphatidylinositol-3-kinase/Protein Kinase B (PI3K/AKT) and Nucleotide-Binding Oligomerization Domain-like Receptor Family Pyrin Domain Containing 3 (NLRP3) Inflammasome Modulation Underlies the Neuroprotective Effects of Vildagliptin in a Rotenone-Induced Mouse Model of Parkinson's Disease. (PubMed, ACS Pharmacol Transl Sci) - "In silico analyses, including molecular docking as well as molecular dynamics simulation, demonstrate good binding affinity as well as stable interaction of vildagliptin with PI3K (4YKN) and NLRP3 (7ALV) proteins in comparison to other DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin). These findings collectively suggest that vildagliptin rendered neuroprotection by PI3K/AKT activation and inhibition of NLRP3-mediated neuroinflammation and apoptosis. In conclusion, we can say that vildagliptin possesses definitive neuroprotective potential as a disease-modifying therapy that warrants further clinical exploration."

Journal • Preclinical • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Type 2 Diabetes Mellitus • IL1B • NLRC5 • NLRP3

Simple and cost-effective UV spectrophotometric platforms integrating advanced green and blue metrics for concurrent analysis of dapagliflozin and vildagliptin in diabetes therapy. (PubMed, Sci Rep) - "Method greenness was evaluated using Eco-scale, GAPI, MoGAPI, CaFRI, and blueness assessment, while CACI was applied to assess overall analytical performance. Statistical comparison between the methods showed no significant differences."

HEOR • Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid in an Elderly Woman With Type 2 Diabetes Mellitus: A Case Report. (PubMed, Cureus) - "DPP-4 inhibitors as a class have been associated with BP, with the strongest evidence reported for vildagliptin, although cases involving linagliptin have also been documented. Linagliptin was discontinued, and treatment with prednisone was initiated, resulting in progressive improvement and complete cessation of new blister formation at follow-up. This case highlights the importance of recognizing medication-induced BP in older diabetic patients and reviews current evidence regarding the epidemiology, pathogenesis, clinical presentation, diagnosis, and management of DPP-4 inhibitor-associated BP."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Drug repurposing of liver cancer based on multimodal neural network and virtual screening. (PubMed, Anticancer Drugs) - "Further verification of their in-vitro activity was performed through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and wound healing assays in MHCC97-H, HepG2, and Huh7 cell lines, revealing that Manidipine and Vildagliptin exhibited significant cytotoxicity and migration inhibition. These results demonstrate the feasibility of the proposed screening workflow and provide a set of candidate molecules for further mechanistic investigation in liver cancer drug repurposing."

Journal • Liver Cancer • Oncology • Solid Tumor

Targeting the sEH–EET axis with DPP-4 inhibitor and ARNI ameliorates portal hypertension in experimental cirrhosis (EASL 2026) - "Thereafter, rats received oral administration of vehicle, vildagliptin (10 mg per kg), sacubitril/valsartan (30 mg per kg), combined vildagliptin and sacubitril/valsartan, or carvedilol (10 mg per kg) for an additional six weeks. DPP-i and ARNI improved portal hypertension and liver fibrosis and demonstrated additive benefits when combined. This therapeutic strategy may represent a novel treatment option for cirrhosis- associated portal hypertension."

Cardiovascular • Fibrosis • Hepatology • Hypotension • Immunology • Liver Cirrhosis • Nephrology • Portal Hypertension • Renal Disease • ACTA2 • CD34 • COL1A1 • CTGF • NOS3 • PACERR • PTGS2 • TGFB1

Safety and Tolerability of Vildagliptin 100 mg Sustained-Release Formulation in Type 2 Diabetes Mellitus: Results From a Prospective, Multicenter, Single-Arm, Post-marketing Surveillance Study. (PubMed, Cureus) - "This study demonstrated that vildagliptin 100 mg SR once daily monotherapy given over 24 weeks was well tolerated and effective in patients with T2DM. It effectively controlled glycemic parameters with no significant adverse events or harmful renal or hepatic effects."

Journal • P4 data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of the therapeutic effect of new hypoglycemic drugs on patients with heart failure with reduced ejection fraction and type 2 diabetes: a systematic review and network meta-analysis. (PubMed, Front Cardiovasc Med) - "Notably, Dapagliflozin improved LVEF more effectively than controls (MD -2.94%; 95% CI -3.89, -1.99). Among patients with HFrEF and T2DM, Empagliflozin significantly reduced NT-proBNP plasma levels vs. placebo (SMD -0.61; 95% CI -0.91, -0.31)...Notably, Sotagliflozin demonstrates potentially favorable effects for primary cardiovascular endpoints, whereas Vildagliptin appears to be more effective for HbA1c reduction in this analysis. PROSPERO CRD420251269519."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Ameliorative effects of Wiryeongtang (herbal medicine) on cardiorenal complications via modulation of inflammatory and fibrotic responses in diabetic mice. (PubMed, Integr Med Res) - "Four groups were studied: a non-diabetic control (db/m), an untreated diabetic group (db/db), a vildagliptin-treated group (50 mg/kg/day) as a positive control, and a WRT-treated group (200 mg/kg/day)...The findings suggest that WRT may serve as a potential therapeutic agent for managing cardiorenal complications associated with type 2 diabetes. It alleviated hyperglycemia, improved insulin sensitivity, and reduced inflammation and fibrosis in both cardiac and renal tissues through anti-apoptotic and anti-fibrotic mechanisms."

IO biomarker • Journal • Preclinical • Cardiomyopathy • Cardiovascular • Diabetes • Diabetic Nephropathy • Fibrosis • Glomerulonephritis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • BAX • BCL2 • CASP3 • CASP9

Machine learning-assisted and simulation-based elucidation of phytochemical dipeptidyl peptidase-4 inhibitors towards safer therapeutics for diabetes. (PubMed, Comput Biol Chem) - "Through protein docking with DPP-4 (PDB ID: 6B1E), coumarin, eugenol and cinnamic acid were highlighted as having a high binding affinity when compared to the known inhibitor Vildagliptin...In addition to the molecular information, the results of the protein interaction and pathway enrichment analysis indicated that DPP-4 has many functions related to the regulation of insulin secretion and inflammatory processes through a complex network. Therefore, these studies support the use of phytochemical compounds as safe DPP-4 Inhibitors, and offer a new approach for rapid identification of plant-derived compounds for the treatment of T2DM."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Acute Kidney Injury in Patients With Diabetes Mellitus: A Disproportionality Analysis Based on the FAERS. (PubMed, In Vivo) - "This study suggests that some DPP4is, including linagliptin, sitagliptin and vildagliptin, are associated with AKI, even without concomitant use of an AKI inducer. Given the widespread use of DPP4is and the severity of AKI, clinicians should be sufficiently informed about their potential relationship."

Journal • Acute Kidney Injury • Diabetes • Metabolic Disorders • Nephrology • Renal Disease

Vildagliptin alleviates cardiomyocyte apoptosis and inflammatory responses in the treatment of non-valvular atrial fibrillation by regulating the NO/sGC/cGMP signaling pathway. (PubMed, Immunopharmacol Immunotoxicol) - "In comparison with the AFG, rats in the DG showed significant increases in ERP, APD90, and the ERP/APD90 ratio, along with pronounced reductions in inflammatory cytokine levels and cardiomyocyte AI. Vildagliptin can markedly improve the myocardial electrical and vascular functions and reduce cardiomyocyte apoptosis and inflammatory responses in NVAF."

Journal • Atrial Fibrillation • Cardiovascular • Inflammation • PDE5A

Docosahexaenoic acid is comparable to vildagliptin in improving hyperglycemia and pancreatic insulin signaling of diabetic rats via SIRT1/Akt/PI3K pathway. (PubMed, Sci Rep) - "Moreover, both Vilda and DHA significantly increase gene expression of SIRT1, Akt, and PI3K and markedly restored normal pancreatic tissue architecture compared with diabetic control group. DHA was comparable to Vilda as insulinotropic and anti-hyperglycemic agent in T2D rats via activation of SIRT1/Akt/PI3K pathway & reducing oxidative stress."

Journal • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CAT

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (clinicaltrials.gov) - P3 | N=186 | Recruiting | Sponsor: Centre Hospitalier Universitaire de Besancon | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Transplantation

Neuroprotective effects of DPP-4 inhibitors sitagliptin and vildagliptin in Parkinson's disease via autophagy modulation. (PubMed, 3 Biotech) - "Together, these results position sitagliptin and vildagliptin as promising autophagy-modifying candidates for disease-modifying PD therapy. The online version contains supplementary material available at 10.1007/s13205-026-04761-8."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • AKT1

DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs. (PubMed, Front Cell Dev Biol) - "To further elucidate its role in the development of MAFLD, we inhibited DPP4 activity with vildagliptin (VILDA) and analyzed the global transcriptomic changes and specific gene and protein gene expression of steatosis-associated genes with and without DPP4 inhibition...Our in vitro HLC-model reproduced the DPP4-dependent aspects of the disease and responded positively to VILDA treatment. Further elucidation of the role of DPP4 in the etiology of MAFLD and other diseases is warranted."

Journal • Diabetes • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Oncology • Renal Disease • Type 2 Diabetes Mellitus • DPP4

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Sex-, age-, and weight-related differences were noted for dulaglutide, liraglutide, semaglutide, sitagliptin, linagliptin, alogliptin, and saxagliptin. Median onset was shorter for GLP-1 RAs and tirzepatide (≤ 30 days) and longer for DPP-4is (55-132 days), with vildagliptin latest...Musculoskeletal AEs associated with incretin therapies differ by drug class and onset timing. Vigilant monitoring is needed during early GLP-1 RA or tirzepatide therapy and later during DPP-4i use to optimize patient safety."

Adverse events • Journal • Back Pain • Diabetes • Immunology • Metabolic Disorders • Muscular Atrophy • Musculoskeletal Diseases • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus